Ameritas Investment Partners, Inc. Immuneering Corp Transaction History
Ameritas Investment Partners, Inc.
- $2.84 Billion
- Q2 2024
Shares
3 transactions
Others Institutions Holding IMRX
# of Institutions
60Shares Held
9.65MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$5.01 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.85 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$2.54 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD859KShares$2.29 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.97 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $70.2M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...